- Conditions
- Colon Cancer
- Interventions
- Colorectal cancer screening pamphlet
- Other
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 274 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Colorectal Cancer, Breast Cancer, Healthy
- Interventions
- Not listed
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
- Interventions
- CP-383
- Drug
- Lead sponsor
- Tasca Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
- Conditions
- Resectable Pancreatic Cancer
- Interventions
- Gemcitabine and Abraxane
- Drug
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Grand Rapids, Michigan • Minneapolis, Minnesota + 1 more
- Conditions
- Seriously Ill Patients, Cancer, Heart Failure, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, End-stage Renal Disease, End-stage Liver Disease, Dementia
- Interventions
- Clinician Implementation Strategy Stage 1: low intensity clinician training, Clinician Implementation Strategy Stage 2: high intensity clinician training, Low patient engagement, High patient engagement
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Palo Alto, California • West Los Angeles, California • Aurora, Colorado
- Conditions
- Esophageal Cancer
- Interventions
- Radiation, FMISO PET CT
- Radiation · Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
- Interventions
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus, Valproic Acid
- Biological · Other · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Rectal Cancer, for Bowel Dysfunction Following Surgery for Rectal Cancers
- Interventions
- Implantation of the InterStimTM, MSK BFI questionnaires, The Low Anterior Resection Score (LARS) questionnaires, The EuroQOL5D questionnaires, The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires
- Device · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Endocrine Tumors/ Neuroendocrine Tumors
- Interventions
- Pembrolizumab (Keytruda), Fludarabine, Cyclophosphamide, Aldesleukin, Young TIL
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 72 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Esophageal Cancer
- Interventions
- filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 97
- States / cities
- Burbank, California • Hayward, California • Mission Hills, California + 72 more
- Conditions
- Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
- Interventions
- Biospecimen Collection
- Procedure
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2035
- U.S. locations
- 8
- States / cities
- La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
- Conditions
- Pancreatic Cancer
- Interventions
- VectRx Thermal Therapy
- Device
- Lead sponsor
- NeoTherma Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer, Colon Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,517 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 15
- States / cities
- Orange, California • Colorado Springs, Colorado • Hartford, Connecticut + 12 more
- Conditions
- Colorectal Neoplasms
- Interventions
- JNJ-95437446
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm, Appendiceal Adenocarcinoma, Appendiceal Carcinoid Tumor, Appendiceal Neoplasm Malignant Secondary, Appendix Adenocarcinoma, Appendix Mucinous Neoplasm, Appendix Tumor, Appendix Cancer Metastatic, Appendix NET, Low-Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Adenocarcinoma
- Interventions
- Genetic profiling, Retrospective tissue procurement
- Genetic · Other
- Lead sponsor
- Andreana Holowatyj, PhD, MSCI
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2034
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Pancreatic Carcinoma, Tumors That Express CA19-9
- Interventions
- MVT-2163, MVT-5873
- Drug
- Lead sponsor
- BioNTech Research & Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer
- Interventions
- Booklet, Audio CD, Video with Non-Moving Images, Video with Animated Images, Questionnaires
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 189 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2020
- U.S. locations
- 4
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Pancreatic Cancer
- Interventions
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
- Biological · Procedure · Radiation
- Lead sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 3
- States / cities
- Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Colorectal Cancer
- Interventions
- RAD001, FOLFOX, Bevacizumab
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Not listed
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 2
- States / cities
- Salt Lake City, Utah
- Conditions
- Colon Cancer, Colorectal Cancer
- Interventions
- capecitabine, imatinib mesylate
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Barrett Esophagus, Transoral Incisionless Fundoplication
- Interventions
- TIF
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Colorectal Neoplasms
- Interventions
- E-Motivate group, Usual Care Group
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer, Merkel Cell Carcinoma
- Interventions
- SNS-101 (anti-VISTA), Cemiplimab
- Drug
- Lead sponsor
- Sensei Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more
- Conditions
- Rectal Cancer
- Interventions
- Endo-HDR (if randomized to this arm), capecitabine and IMRT (if randomized to this arm), IMRT (intensity modulated radiation therapy), FOLFOX6, Surgery
- Radiation · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 1 more